Monday October 20
Boston Cure Project
According to Crain's New York Business: "The Mount Sinai School of Medicine
has been awarded a $30 million, five-year grant from the National Institute
of Neurological Disorders and Stroke to conduct the first large-scale clinical
trial of combination therapy for the degenerative disease multiple sclerosis.
Currently, two drugs are used to treat the relapsing form of multiple sclerosis
- interferon beta and glatiramer acetate. Both drugs only slow the progression
of the incurable disease and both are expensive. The researchers, who will
be led by Dr. Fred Lublin, director of Mount Sinai's Corinne Goldsmith
Dickinson Center for Multiple Sclerosis, plan to design a national trial
to see if the drugs work better together than they do separately."
Copyright © 2003, Boston Cure Project